Table 2.
IC50 values for oncology drugs tested on SUM149 cells in qHTS and confirmation MTT and Hoechst assays.
| qHTS MTTa IC50 (μM) |
Confirmation MTTb IC50 (μM) |
Hoechstc IC50 (μM) |
Drug classd | |
|---|---|---|---|---|
| Dactinomycin | <0.02 | 0.027 | <0.02 | Antineoplastic antibiotic |
| Plicamycin | <0.02 | 0.028 | 0.12 r | Antineoplastic antibiotic |
| Bortezomib | <0.02 | 0.029 | <0.02 | Proteosome inhibitor |
| Doxorubicin | <0.02 | 0.70 | <0.05 | Anthracycline |
| Daunorubicin | <0.02 | 0.25 | 0.04 | Anthracycline |
| Fludarabine | 2.1 ± 1.1 | 0.48 | 0.45 | Antimetabolite |
| Mitoxantrone | 2.5 ± 0.6 | 3.08 | 0.20 | Anthracenedione antineoplastic antibiotic |
| Sorafenib | 4.5 ± 0.4 | 3.93 | 8.69 | Kinase inhibitor |
| Sunitinib | 5.0 ± 0.8 | 5.55 | 6.10 | Kinase inhibitor |
| Gefitinib | 6.2 ± 2.3 | 7.27 | 14.10 | Kinase inhibitor |
| Vorinostat | 8.9 ± 4.9 | 2.44 | 2.02 | HDAC inhibitor |
| Lapatinib | 9.0 ± 0.3 | 10.85 | 6.73 | Kinase inhibitor |
| Mitomycin | 9.1 ± 0.4 | 1.61 | 0.53 | Antineoplastic antibiotic |
| Bleomycin | 13.8 ± 2.0 | 0.82 | 0.30 | Antineoplastic antibiotic |
| Capecitabine | 15.0 ± 9.5 | 17.51 | >20 | Antimetabolite |
aIC50 values derived from qHTS screen of complete approved oncology drug set (89 drugs originally obtained from NCI DTP in plate format). Average and SD values derived from minimum of three independent experiments. The approved oncology drugs were resourced from the NCI DTP as dry powders and retested in MTTb and Hoechstc assays as described in Materials and Methods. dSee supplementary Table 2 for full listing of drug class and mechanism of action for the approved oncology drug set.